1. Home
  2. GILD
  3. GILD News

Latest Gilead Sciences Inc. (GILD) News on January 20, 2025

House of the Week: A Riverfront Retreat in Southeastern Connecticut
GILD

The Wall Street Journal

2 days ago

House of the Week: A Riverfront Retreat in Southeastern Connecticut

The Zacks Analyst Blog Salesforce, Shell and Gilead Sciences
GILD

Zacks

3 days ago

The Zacks Analyst Blog Salesforce, Shell and Gilead Sciences

Top Stock Reports for Salesforce, Shell, Gilead Sciences & Others
GILD

Zacks

3 days ago

Top Stock Reports for Salesforce, Shell, Gilead Sciences & Others

Is Gilead Sciences (GILD) Among the Best NASDAQ Dividend Stocks to Buy?
GILD

Insider Monkey

3 days ago

Is Gilead Sciences (GILD) Among the Best NASDAQ Dividend Stocks to Buy?

Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
GILD

Zacks

4 days ago

Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?

Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing
GILD

Zacks

4 days ago

Gilead Sciences (GILD) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Gilead Sciences, US government settle patent case over HIV prevention drugs
GILD

Reuters

4 days ago

Gilead Sciences, US government settle patent case over HIV prevention drugs

Gilead, LEO Pharma Partner in $1.7 Billion Deal for Inflammatory Disease Therapies
GILD

GuruFocus.com

6 days ago

Gilead, LEO Pharma Partner in $1.7 Billion Deal for Inflammatory Disease Therapies

Gilead and LEO Pharma link on programmes for inflammatory conditions
GILD

Pharmaceutical Technology

6 days ago

Gilead and LEO Pharma link on programmes for inflammatory conditions

GILD

MT Newswires

7 days ago

Gilead Sciences Partners With LEO Pharma on Inflammatory Disease Therapies

Gilead, LEO Pharma partner to develop programs for inflammatory diseases
GILD

Reuters

8 days ago

Gilead, LEO Pharma partner to develop programs for inflammatory diseases

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases
GILD

Business Wire

8 days ago

Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases

GILD

MT Newswires

9 days ago

Redburn Atlantic Adjusts Price Target on Gilead Sciences to $125 From $123, Keeps Buy Rating

GILD

Investing.com

9 days ago

Morgan Stanley upgrades Gilead on HIV treatment growth

GILD

MT Newswires

10 days ago

Morgan Stanley Upgrades Gilead Sciences to Overweight From Equalweight, Raises Price Target to $113 From $87

GILD

MT Newswires

10 days ago

Morgan Stanley Upgrades Gilead Sciences to Overweight From Equalweight, Adjusts Price Target to $113 From $87

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
GILD

Zacks

10 days ago

Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know

GILD

MT Newswires

12 days ago

Galapagos Plans to Split Into Two Entities, Revise Agreement With Gilead Sciences, Reduce Workforce by 40%

GILD

MT Newswires

13 days ago

RBC Trims Price Target on Gilead Sciences to $83 From $84, Keeps Sector Perform Rating

Here’s Why TCW Relative Value Large Cap Fund Exited its Position in Gilead Sciences (GILD)
GILD

Insider Monkey

14 days ago

Here’s Why TCW Relative Value Large Cap Fund Exited its Position in Gilead Sciences (GILD)

Gilead Sciences, Inc. (GILD): A Bull Case Theory
GILD

Insider Monkey

14 days ago

Gilead Sciences, Inc. (GILD): A Bull Case Theory

Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors
GILD

Zacks

16 days ago

Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors

Five Best: Novels in Letters
GILD

The Wall Street Journal

17 days ago

Five Best: Novels in Letters

Is Gilead Sciences, Inc. (GILD) the Best Dividend Stock of 2024?
GILD

Insider Monkey

20 days ago

Is Gilead Sciences, Inc. (GILD) the Best Dividend Stock of 2024?

Is Gilead Sciences, Inc. (GILD) the Best Pharma Dividend Stock to Buy In 2024?
GILD

Insider Monkey

20 days ago

Is Gilead Sciences, Inc. (GILD) the Best Pharma Dividend Stock to Buy In 2024?

Gilead Buys $20.1 Million of Assembly Biosciences Stock
GILD

Barrons.com

22 days ago

Gilead Buys $20.1 Million of Assembly Biosciences Stock

Jim Cramer on Gilead Sciences, Inc. (GILD): ‘I Don’t Think The Business Is Worth As Much As The Stock Is Selling’
GILD

Insider Monkey

24 days ago

Jim Cramer on Gilead Sciences, Inc. (GILD): ‘I Don’t Think The Business Is Worth As Much As The Stock Is Selling’

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
GILD

Zacks

25 days ago

Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know

Here's How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock
GILD

Benzinga

25 days ago

Here's How You Can Earn $100 In Passive Income By Investing In Gilead Sciences Stock

Exploring Three High Growth Tech Stocks In The United States
GILD

Simply Wall St.

a month ago

Exploring Three High Growth Tech Stocks In The United States

Gilead Sciences Stock Today: Boost Your Return With This Covered Call Trade
GILD

Investor's Business Daily

a month ago

Gilead Sciences Stock Today: Boost Your Return With This Covered Call Trade

Gilead Sciences (GILD) Made Big Announcements in Q3
GILD

Insider Monkey

a month ago

Gilead Sciences (GILD) Made Big Announcements in Q3

How To Invest: The Slow Saucer Base Can Produce Quick Returns
GILD

Investor's Business Daily

a month ago

How To Invest: The Slow Saucer Base Can Produce Quick Returns

Gilead Sciences to Present at Upcoming Investor Conference
GILD

Business Wire

a month ago

Gilead Sciences to Present at Upcoming Investor Conference

Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
GILD

Zacks

a month ago

Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?
GILD

Zacks

a month ago

Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year?

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
GILD

Zacks

a month ago

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

GILD

MT Newswires

a month ago

Assembly Biosciences Says It Will Receive $30.1 Million Funding From Gilead Sciences

GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer
GILD

Zacks

a month ago

GILD's Trodelvy Gets Second Breakthrough Therapy Tag for Lung Cancer

Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains
GILD

Zacks

a month ago

Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX Gains

Gilead, Terray Therapeutics announce research collaboration
GILD

TipRanks

a month ago

Gilead, Terray Therapeutics announce research collaboration

Gilead and Terray link to develop small-molecule therapies
GILD

Pharmaceutical Technology

a month ago

Gilead and Terray link to develop small-molecule therapies

GILD

MT Newswires

a month ago

Gilead Sciences' Trodelvy Granted FDA Breakthrough Designation for Treating Extensive-Stage Small Cell Lung Cancer

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
GILD

Business Wire

a month ago

U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer

GILD

MT Newswires

a month ago

Gilead Sciences, Terray Therapeutics to Collaborate on Novel Small Molecule Therapies

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
GILD

Business Wire

a month ago

Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies

GILD Obtains Positive CHMP Opinion for Liver Disease Drug
GILD

Zacks

a month ago

GILD Obtains Positive CHMP Opinion for Liver Disease Drug

Gilead (GILD) Upgraded to Buy: Here's Why
GILD

Zacks

a month ago

Gilead (GILD) Upgraded to Buy: Here's Why

Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know
GILD

Zacks

a month ago

Gilead Sciences (GILD) Stock Moves -0.57%: What You Should Know

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
GILD

Benzinga

a month ago

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report

GILD

MT Newswires

a month ago

Gilead Sciences Says EU Panel Recommends Seladelpar for Primary Biliary Cholangitis

Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
GILD

Business Wire

a month ago

Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis

Gilead appoints Sanofi official Dietmar Berger as next chief medical officer
GILD

Reuters

a month ago

Gilead appoints Sanofi official Dietmar Berger as next chief medical officer

GILD

MT Newswires

a month ago

Gilead Sciences Names Dietmar Berger as Chief Medical Officer

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
GILD

Business Wire

a month ago

Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer

Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
GILD

Benzinga

a month ago

Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing

Is Gilead Sciences (GILD) Stock Undervalued Right Now?
GILD

Zacks

a month ago

Is Gilead Sciences (GILD) Stock Undervalued Right Now?

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
GILD

Zacks

a month ago

Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Looking For Yields: IDACORP, Gilead Sciences and Fifth Third Bancorp Are Consistent Moneymakers
GILD

Benzinga

a month ago

Looking For Yields: IDACORP, Gilead Sciences and Fifth Third Bancorp Are Consistent Moneymakers

GILD

MT Newswires

a month ago

Leerink Partners Adjusts Gilead Sciences Price Target to $99 From $96, Maintains Outperform Rating

GILD

MT Newswires

a month ago

Gilead Sciences, Arcellx's CAR-T Therapy Supports 2030 Oncology Ambitions, Oppenheimer Says

GILD

MT Newswires

a month ago

Oppenheimer Adjusts Price Target on Gilead Sciences to $115 From $105, Maintains Overweight Rating

GILD

MT Newswires

a month ago

Oppenheimer Adjusts Price Target on Gilead Sciences to $115 From $105, Keeps Outperform Rating

The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group
GILD

Zacks

a month ago

The Zacks Analyst Blog Highlights Eli Lilly, AbbVie, Gilead Sciences, Air T and Fossil Group

GILD

MT Newswires

a month ago

Gilead Sciences Unit Says Followup Data Support 'Durable' Efficacy of Tecartus CAR T-Cell Therapy

Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
GILD

Business Wire

a month ago

Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024

Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
GILD

Business Wire

a month ago

Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
GILD

Investor's Business Daily

a month ago

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.

Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences
GILD

Zacks

a month ago

Top Stock Reports for Eli Lilly, AbbVie & Gilead Sciences

Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
GILD

Business Wire

a month ago

Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH

Gilead Sciences Is Turning Itself Around. Why Its Stock Can Keep Rallying.
GILD

Barrons.com

a month ago

Gilead Sciences Is Turning Itself Around. Why Its Stock Can Keep Rallying.

Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC
GILD

Zacks

2 months ago

Gilead Collaborates With German Biotech Tubulis for Solid Tumor ADC

GILD

MT Newswires

2 months ago

HSBC Adjusts Price Target on Gilead Sciences to $82 From $69

GILD

MT Newswires

2 months ago

Gilead Sciences Insider Sold Shares Worth $23,065,271, According to a Recent SEC Filing

PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy
GILD

Zacks

2 months ago

PPBT Stock Surges 150% on Superior Efficacy of PDAC Combo Therapy

Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
GILD

Zacks

2 months ago

Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?

GILD

MT Newswires

2 months ago

Gilead Sciences Partners With Tubulis on Antibody-Drug Conjugate Development for Solid Tumors

Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
GILD

Business Wire

2 months ago

Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target

GILD

Morningstar Research

2 months ago

Analyst Report: Gilead Sciences, Inc.

GILD

MT Newswires

2 months ago

Jefferies Raises Price Target on Gilead Sciences to $115 From $105

Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?
GILD

Zacks

2 months ago

Gilead Stock Surges 44.2% in 6 Months: Time to Buy or Sell?

GILD vs. VRTX: Which Stock Should Value Investors Buy Now?
GILD

Zacks

2 months ago

GILD vs. VRTX: Which Stock Should Value Investors Buy Now?

Gilead announces PURPOSE 2 trial data published in NEJM
GILD

TipRanks

2 months ago

Gilead announces PURPOSE 2 trial data published in NEJM

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
GILD

Zacks

2 months ago

Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know

Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
GILD

Clinical Trials Arena

2 months ago

Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial

Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
GILD

Business Wire

2 months ago

Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results

Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech
GILD

Pharmaceutical Technology

2 months ago

Gilead adds investigational HIV vaccine to its portfolio from Spanish biotech

Exploring Three High Growth Tech Stocks In The United States
GILD

Simply Wall St.

2 months ago

Exploring Three High Growth Tech Stocks In The United States

GILD

Argus Research

2 months ago

Weekly Stock List

GILD

MT Newswires

2 months ago

UBS Raises Price Target on Gilead Sciences to $96 From $70, Maintains Neutral Rating

Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program
GILD

TipRanks

2 months ago

Hookipa Pharma announces workforce reduction of 80%, pause of eseba-vec program

GILD

MT Newswires

2 months ago

Mizuho Securities Adjusts Price Target on Gilead Sciences to $100 From $90

GILD

Argus Research

2 months ago

Analyst Report: Gilead Sciences, Inc.

GILD

Argus Research

2 months ago

Market Digest: ADTN, EQR, GILD, NFG, PRU, MSCI

GILD

MT Newswires

2 months ago

Daiwa Securities Adjusts Gilead Sciences Price Target to $90 From $73

GILD

MT Newswires

2 months ago

RBC Capital Adjusts Gilead Sciences Price Target to $84 From $81

Gilead’s Livdelzi shows promise in PBC clinical trial
GILD

Clinical Trials Arena

2 months ago

Gilead’s Livdelzi shows promise in PBC clinical trial

GILD

Morningstar Research

2 months ago

Analyst Report: Gilead Sciences, Inc.

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
GILD

Benzinga

2 months ago

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease

GILD

MT Newswires

2 months ago

Gilead Sciences Says Most of Phase 3 Primary Biliary Cholangitis Participants Treated With Livdelzi Achieved Biochemical Response

Share on Social Networks: